BiotechTV

BiotechTV - News

Science EN ↓ 529 episodes

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Be sure to visit the podcast's website and support the creator: podcasters.spotify.com

Author

BiotechTV

Category

Science

Podcast website

podcasters.spotify.com

Latest episode

Nov 18, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

SF Healthcare Week: Roivant CEO Matt Gline provides an update on the 'vant ecosystem 15.01.2026

He discusses key data in the year ahead including from Immunovant and Priovant. Plus, an update on the lawsuits regarding covid vaccine LNP delivery IP and how he thinks about Roivant's cash balance.

SF Healthcare Week: Astellas Pharma CEO Naoki Okamura describes the type of assets the company looks for externally, and covers key internal pipeline assets 15.01.2026

He talks about KRAS degraders, claudin 18.2, AAV gene therapy, and more. Plus, how Astellas thinks about the coming patent expiry of Xtandi.

SF Healthcare Week: Soleno Therapeutics' Chairman & CEO Anish Bhatnager discusses the launch of its Prader-Willi syndrome therapy VYKAT XR 15.01.2026

He describes the launch, physician and patient feedback, and responds in his own words to short seller criticism.

SF Healthcare Week: Madrigal CEO Bill Sibold talks about the commercialization of the MASH treatment Rezdiffra, and two bolt on deals the company has done for combinations 14.01.2026

He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.

SF Healthcare Week: Insmed CEO Will Lewis discusses the launch BRINSUPRI and pipeline readouts ahead in 2026 14.01.2026

He discusses the $145M 4Q number that was announced at JPM, and the real world feedback the company has been receiving from physicians and patients. Plus, how the thinks about Insmed now that it is a $35B market cap company.

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more 12.01.2026

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

SF Healthcare Week: Flagship Pioneering's Founder Noubar Afeyan shares his thoughts on the image of science in the United States today, biotech's roller coaster 2025, mRNA, AI, and more 12.01.2026

He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

SF Healthcare Week: Baird Senior Analyst Brian Skorney comments on Monday's conference news and highlights his top picks ahead for 2026 12.01.2026

He discusses Biohaven, Xenon, Biogen, and Sarepta.

SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy 12.01.2026

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy 12.01.2026

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.

SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year 12.01.2026

He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance setting for UC and Crohn's later this year.

Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year 07.01.2026

He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026 30.12.2025

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza 29.12.2025

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects.

Create Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells." 12.12.2025

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization 11.12.2025

CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today 11.12.2025

Founder and CEO Michelle Lee highlights the key distinction between Medra and other automated lab equipment, which is that Medra's platform is designed to sense and understand its environment and use that knowledge to make its own intelligent decisions.

Kymera Therapeutics' Founder & CEO Nello Mainolfi recaps Monday's STAT6 data and discusses the next steps in development 10.12.2025

He talks about Kymera's dosing methodology, and recaps the data from a degredation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation 09.12.2025

Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week 09.12.2025

Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in the United States.

ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftcoclax, which was recently approved in China and is in multiple global registration studies 09.12.2025

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, and update on global studies of the BCR-ABU/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor.

ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know 09.12.2025

He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighting atopic dermatitis data that will be coming in January.

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I 08.12.2025

He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.

ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed highlights the company's FLT3xCD3 bispecific T-cell engager data at ASH in AML and MDS 08.12.2025

He describes how this asset binds to the extracellular domain and therefore can work for both wild type patients and those with mutations. Plus, recent regulatory news on zipalertinib and when to expect to see autoimmune data.

ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting 08.12.2025

He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.

Listen to the BiotechTV - News podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.